Alemtuzumab is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Alemtuzumab becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Browse Alphabetically:
A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #
Information about ExpressMedsCanada.com
List of countries where we can ship Alemtuzumab:
Latest news releases on Alemtuzumab:
no antibody induction vs ATG vs IL-2R blockade vs alemtuzumab Significantly higher rate of DGF in ATG group [116] Lymphocyte depletion (alemtuzumab) Retrospective analysis of data from US transplant database comparing outcomes of 14,362 ...
Starting with the recent launch of fully human, recombinant antibodies binding Rituximab (Rituxan ®) and Trastuzumab (Herceptin ®), AbD Serotec plans to expand this product category with antibodies against Alemtuzumab (Campath ®), Bevacizumab ...
Starting with the recent launch of fully human, recombinant antibodies binding Rituximab (Rituxan(®)) and Trastuzumab (Herceptin(®)), AbD Serotec plans to expand this product category with antibodies against Alemtuzumab (Campath(®)), Bevacizumab ...
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(R)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated ...
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development.
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated ...
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated ...
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's ...